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Alzheimer’s disease (AD) is a complex, neurodegenerative disorder characterized by the presence of amyloid plaques and
neurofibrillary tangles in the brain. Glial cells, particularly microglial cells, react to the presence of the amyloid plaques and
neurofibrillary tangles producing an inflammatory response. While once considered immunologically privileged due to the blood-
brain barrier, it is now understood that the glial cells of the brain are capable of complex inflammatory responses. This paper will
discuss the published literature regarding the diverse roles of neuroinflammation in the modulation of AD pathologies. These data
will then be related to the well-characterized macrophage phenotypes. The conclusion is that the glial cells of the brain are capable
of a host of macrophage responses, termed M1, M2a, M2b, and M2c. The relationship between these states and AD pathologies
remains relatively understudied, yet published data using various inflammatory stimuli provides some insight. It appears that
an M1-type response lowers amyloid load but exacerbates neurofibrillary tangle pathology. In contrast, M2a is accompanied by
elevated amyloid load and appears to ameliorate, somewhat, neurofibrillary pathology. Overall, it is clear that more focused, cause-
effect studies need to be performed to better establish how each inflammatory state can modulate the pathologies of AD.
1. Introduction
Alzheimer’s disease (AD) is defined as the presence of
amyloid plaques composed of amyloid-beta (Aβ) peptide
aggregates and neurofibrillary tangles composed of hyper-
phosphorylated and aggregated tau protein. Neuroinflam-
mation has been known to be present in AD since the
original description of the histopathology of AD by Alois
Alzheimer in 1907, who described “gliose,” inflammation
of the glia. Since then, it has been shown in numerous
studies, both mouse and human, that glial cells respond to
the presence of AD pathological lesions (plaques and tangles)
by morphologically changing their characteristics, expressing
numerous cell surface receptors and surrounding the lesions
[1, 2]. The prevailing view of neuroinflammation in AD for
many years has been that it is an on-off phenomenon that
contributes to the cytotoxicity of AD lesions and therefore
contributes to the neurodegeneration in AD [3]. It is only
within the recent decade that neuroinflammation has come
to the forefront of AD research, not only with respect to
its contribution to the neurodegenerative process, but also
for its role in the clearance of AD lesions and beneficial
contribution to AD progression. The dichotomy of the
research findings on the role(s) of neuroinflammation in AD
may be explained by the capacity of glial cells to generate
multiple distinct phenotypes dependent upon the stimuli
present.
Glial cells describe the nonneuronal cells of the brain
and include microglia, astrocytes, oligodendrocytes, and per-
icytes. These accessory cells are critical for the maintenance
of an appropriate environment in which the neuronal cells
can function optimally. This includes, but not limited to,
ionic and osmotic homeostasis, myelination, debris removal,
and neurotransmitter uptake and recycling. All glial cells
are capable of achieving some degree of inflammatory
response; however, the key cell type for the initiation,
regulation, and resolution of the inflammatory response
is considered to be the microglial cell. Derived from the
macrophage cell lineage, microglia are specialized tissue
macrophages in the brain and are capable of a broad range
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of inflammatory responses dependent upon the stimulus.
This paper will summarize the published literature regarding
different activation states of microglia and their subsequent
impact on AD pathologies. This paper will then discuss how
the field can use data from the peripheral macrophage body
of literature to better characterize microglial activation states
and begin to predict what impact each state will have on
the progression of AD.
2. Microglia in AD
For many years the body of literature regarding microglial
cells and their role in AD focused on the negative influence
inflammation would be thought to have on the progression
of AD. This primarily focused on the concept of the autotoxic
loop. Described in 1998 by E. G. McGeer and P. L. McGeer as
a “vicious cycle,” the autotoxic loop is the description of the
microglial activation in response to cellular debris in the AD
brain, this microglial activation is then thought to result in
the release of cytotoxic cytokines that then leads to a more
rapid neuronal death, thus providing more cellular debris to
further accelerate this process [3]. Evidence for this process
stemmed from the finding that there are increased cytokine
levels in the brains and CSF of AD patients. These cytokines,
primarily IL-1β and TNFα, are known to be toxic to cells in
culture and also toxic in the brain if injected into the brain
parenchyma (reviewed in [4]). While there has been some
evidence for the presence of an autotoxic loop, much of the
body of literature suggests that the levels of cytokines are
not great enough, or sustained enough in the AD brain to
cause significant neuronal damage. Attempts to recreate the
autotoxic loop led to some surprising findings, mostly that
the initiation of an inflammatory response in the brain often
leads to the clearance of amyloid plaques in transgenic mouse
models.
Table 1 summarizes some of the studies that have
stimulated inflammatory responses. It is initially apparent in
Table 1 that most studies that have stimulated inflammation
and activated microglia result in reduced amyloid load and
do not present evidence of exacerbated neuronal degenera-
tion. These data do not disprove the autotoxic loop, instead
they suggest a much greater complexity to the inflammatory
response of the brain than originally considered possible.
Lipopolysaccharide (LPS) is a gram-negative bacterial
cell-surface proteoglycan that stimulates an innate immune
response. Injection of LPS into the brain parenchyma of
aged APP/PS1 mice originally aimed at stimulating the
autotoxic loop resulted in microglial activation and the
rapid reduction of amyloid deposits in the brain [5]. A
later study identified the types of microglial activation
occurring with LPS in wildtype mice using intraparenchymal
LPS injections over a time course of 1, 6, and 24 hours
as well as an extended time course of 3, 7, 14, and 28
days [6]. Over this time course, it was found that most
gene expression changes in inflammatory markers peaked
around the 3-day time point and slowly declined to normal
levels by 14 days. The inflammatory markers examined
included TNFα and IL1β as well as Fcγ receptors and
scavenger receptors. Histologically, the same report found
that microglial expression of cell-surface proteins including
complement receptor 3 (also known as CD11b), CD45,
scavenger receptor A, and Fcγ receptors II and III also
peak around three days and then decline; however, some
markers did not decline to control levels. Importantly,
performance of a similar time course in APP/PS1 mice
demonstrated that the majority of amyloid removal occurred
between the time zero and three days, a small further
decrease occurred at 7 and 14 days, while amyloid levels,
surprisingly, rebounded to near time zero levels by 28 days
[7].
In contrast to the amyloid data, LPS injection into tau
transgenic mice showed opposite effects. Intraparenchymal
injection of LPS into the rTg4510 tau transgenic mice
resulted in exacerbation of tau pathology seven days after
the injection [8]. This was determined by examining several
phosphoepitopes of tau as well as Gallyas’s silver staining-
positive neurofibrillary tangles. In addition to the stan-
dard microglial cell surface markers including CD45, this
study identified additional markers of microglial activation
stimulated by LPS; these were arginase 1 and YM1. The
importance of these markers will be discussed later in this
paper. Additionally, LPS injection into the 3XTg mouse
model of amyloid and tau pathology exacerbated the tau
hyperphosphorylation [9]. These data suggest that tau and
amyloid pathologies have opposite responses to the same
inflammatory stimuli, in this case LPS. Whether this is the
case for all inflammatory stimuli remains to be determined;
however, these data should provide significant caution to the
extrapolation of findings in amyloid depositing mice to the
overall condition of AD.
Anti-Aβ immunotherapy is a potential therapeutic
approach to the treatment of AD that uses either a vaccina-
tion approach [10] or passive immunotherapy approach [11]
to increase levels of circulating anti-Aβ IgG molecules. There
have now been numerous studies showing that this approach
significantly lowers amyloid pathology and enhances behav-
ioral performance in amyloid depositing transgenic mice
(reviewed in [12]). Importantly, we previously performed a
series of studies showing that anti-Aβ antibodies stimulate
an inflammatory response in the brain. This occurs whether
the anti-Aβ antibodies are directly injected into the brain
parenchyma [13] or systemically administered in a passive
immunization protocol [14]. We were also able to show
that inhibition of this inflammatory response attenuates the
amyloid reductions significantly [15, 16]. In contrast to the
LPS studies, we were able to show in a different transgenic
mouse model, the APPSw/NOS2−/− mice that develop
amyloid and tau pathologies, that anti-Aβ immunotherapy
is able to lower both amyloid and tau pathologies while
improving behavioral performance [17]. We examined the
breadth of the inflammatory response in both passively
immunized APP transgenic mice and actively vaccinated
APPSw/NOS2−/− transgenic mice, and we found that anti-
Aβ immunotherapy stimulates the gene expression of IL-1β,
TNFα, and IL-6 while concomitantly reducing the expression
of inflammatory markers associated with wound repair; YM1
and arginase 1 [18]. These data contrast with those found
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Table 1: Summary of some transgenic mouse studies that have modulated inflammation and the effects these modulations had on the
pathology.
Mode of inflammatory
modulation
Genetic model
of AD
Pathological changes observed
References
Amyloid load
Tau
pathology
Neuronal
degeneration
Microglial
“activation”
LPS intracranial
APP/PS1
amyloid
↓ ↑ [5, 7]
LPS intracranial rTg4510 tau ↑ ↑ [8]
Anti-Aβ immunotherapy APP amyloid ↓ ↑ [13, 14]
Anti-Aβ immunotherapy
APP/NOS−/−
amyloid, tau,
neuron loss
↓ ↓ ↓ ↑ [17]
IL-1β overexpression in brain
APP/PS1
amyloid
↓ ↑ [22]
TGFβ overexpression in brain APP amyloid ↓ ↑ [19]
TNFR1 and R2 deletion
3Xtg amyloid
and tau
↑ ↓ [21]
with LPS injection, where IL-1β, TNFα, YM1, and arginase 1
were all significantly elevated.
Genetic overexpression of individual inflammatory
cytokines has yielded data similar to those observed with LPS
and anti-Aβ immunotherapy. Increased expression of TGFβ
by astrocytes results in reduced amyloid deposition and
increased microglial activation in APP amyloid depositing
transgenic mice [19]. In addition, an interesting finding
in this study showed that while parenchymal amyloid
deposition decreased, vascular amyloid deposition (cerebral
amyloid angiopathy (CAA)) increased in a correlative man-
ner. We observed a similar phenomenon with the anti-
Aβ immunotherapy passive immunization studies, where
we found increased CAA despite significantly decreased
parenchymal amyloid deposition [20]. The data from Wyss-
Coray et al. would suggest that inflammatory mechanisms
may at least in part, be responsible for the shifted distribution
of amyloid from the brain parenchyma to the cerebrovascu-
lature.
TNFα and IL-1β are considered the major proinflam-
matory cytokines and are studied as classical markers of
neuroinflammation. Individually, both have been implicated
in an autotoxic loop as both are capable of inducing cell death
in vitro and in vivo. Yet, when these pathways are targeted
in amyloid depositing transgenic mice the data show that
these cytokine pathways may have some beneficial action by
ameliorating amyloid deposition. One study that genetically
deleted TNF receptors I and II in the 3XTg mouse model of
amyloid deposition and tau pathology showed that blocking
TNFα signaling actually increases amyloid deposition and
tau pathology [21]. Increased expression of IL-1β in the hip-
pocampus of APP/PS1 amyloid depositing transgenic mice
by genetic means resulted in reduced amyloid deposition and
enhanced microglial activation [22]. The author suggest that
IL-1β-mediated activation of microglia is the mechanism for
the reductions in amyloid deposition. However, in contrast
to these studies, other studies have shown a clear relationship
between IL-1β and neurodegeneration. In a similar way to
the LPS studies, IL-1β has been shown to be responsible for
tau hyperphosphorylation in an in vitro coculture system
of microglia and neurons [23]. Also, a positive correlation
was observed when examining IL-1β levels compared to
neurodegeneration in the APPV717F transgenic mice [24].
Therefore, while IL-1β may ameliorate amyloid pathology,
it seems that the same pathways may also enhance tau
pathology and neurodegeneration.
The contrasting data in different mouse models, cell cul-
ture models and stimulating agents clearly paints the picture
of a complex process, one that cannot simply be defined as
neuroinflammation.
3. Peripheral Macrophage Inflammatory States
Macrophages are circulating immune effector cells that are
prodigious phagocytes essential for the clearance of cellular
debris and invading pathogens. The macrophages monitor
the tissue environment and respond rapidly to any pertur-
bations that may occur. Both macrophages and microglia
originate from bone marrow hematopoietic stem cells that
undergo differentiation into monocytes. These monocytes
then undergo further differentiation upon reaching their
target tissue to become macrophages, of which there are
several types based on their tissue occupancy, or microglia
if they enter the brain (reviewed in [25]). Macrophages
are well understood to generate a variety of responses
dependent upon the stimuli they are presented with. For
instance, the presence of interferon-γ (IFNγ) or TNFα from
T cells, antigen-presenting cells, or natural killer cells will
stimulate the macrophage to express secrete proinflamma-
tory cytokines and produce oxygen and nitrogen radicals.
This state is termed classically activated or M1-activated
macrophages. The M1 state has high microbicidal activity
and is important as a defense mechanism, yet can also
cause damage to the host if not tightly regulated [26].
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Figure 1: Schematic illustrating the M1, M2a, M2b, and M2c
macrophage inflammatory states.
Indeed, classically activated macrophages are implicated in
the development of autoimmune pathologies [27].
Stimulation of macrophages by IL-4 and/or IL-13
results in an M2a state, sometimes called a wound-healing
macrophage [28]. The M2a macrophage state is character-
ized by high IL-1 receptor antagonist (IL-1Ra) and high
arginase as well as expression of chitinases and other
mediators that are known to contribute to the accumulation
and reorganization of extracellular matrix [29]. The M2a
responses are primarily observed in allergic responses,
extracellular matrix deposition, and remodeling. The M2b
macrophage state is stimulated by immune complexes (IgG
antibody-antigen complexes), toll-like receptor activation,
or IL-1 receptor ligands. This state is a combined M1 and
M2a state, where arginase is high and IL-12 is low, but IL-
1β, IL-6 and TNFα are also high. CD86 also appears to be
a relatively specific marker for the M2b state [30]. Finally,
the M2c macrophage state is stimulated by IL-10 and is
sometimes referred to as a regulatory macrophage with anti-
inflammatory activity [30, 31]. These cells express TGFβ
and high IL-10 as well as matrix proteins such as pentraxin
and versican. The M2c state can also be generated through
the hypothalamic-pituitary axis-derived glucocorticoids that
inhibit the expression of pro-inflammatory cytokine genes
and decrease the mRNA stability of these genes [31].
The M2c macrophages contribute to an environment that
results in defective pathogen killing and enhanced survival
of organisms. The macrophage states are summarized in
Figure 1.
4. Applying the Macrophage Classification
to Microglia and AD
Neuroinflammatory markers have been identified in the
macrophage literature that can be applied to the study
of microglia. Indeed, microglia are capable of expressing
many of the macrophage markers identified in Figure 1.
My laboratory, and others, has shown that the brains of
amyloid-depositing mice, tau transgenic mice, and human
AD expressing IL-1β, TNFα, IL-6, YM1, arginase 1, mannose
receptor, TGFβ, and IL-1Ra, among others. Most recently,
my laboratory has performed in vitro studies on BV2
microglial cells to show that, given the correct stimulus,
these microglial cells can generate very specific macrophage-
like inflammatory responses using the M1, M2a, M2b, and
M2c classifications. Figure 2 shows the gene expression data
obtained from BV2 microglial cells treated for 12 hours with
IFNγ and TNFα to induce an M1 response, IL-4 and IL-
13 to induce an M2a response, anti-Aβ IgG-Aβ immune
complexes to induce and M2b response and, finally, IL-
10 to induce an M2c response. As can be seen from the
graphs in Figure 2, twelve hours of treatment of BV2 cells
induced specific responses characterized by the expression
of markers matching those described in the macrophage
literature. These data suggest that microglia, given the correct
stimuli, are capable of generating a range of responses similar
to the macrophage. It will be important to follow up these
studies in primary microglial cells to confirm that these
findings are not unique to the immortalized BV2 microglial
cell line.
My laboratory recently showed that passive immuniza-
tion with anti-Aβ antibodies results in a shift in the inflam-
matory state of the brains of amyloid depositing transgenic
mice. Tg2576 APPSw transgenic mice aged 18 months are
normally biased to the M2a and M2c inflammatory states.
Following only one month of weekly anti-Aβ antibody
injections, the inflammatory state transitioned from M2a
and M2c to M1; this was maintained following two and three
months of administration [18]. Since the change occurred
prior to significant reductions in amyloid deposition, it
is likely that this inflammatory state transition is, at least
partially, responsible for the reductions in amyloid due to the
passive immunotherapy.
The concept that M1 inflammatory state in the brain is
associated with lower amyloid burden is supported by several
studies that have examined components of this inflammatory
state. For instance, IL-1β overexpression in the hippocampus
of APP/PS1 transgenic mice results in decreased amyloid
burden [22]. IL-1β is an M1 cytokine, so its overexpression
may be reproducing the effect of an M1 neuroinflammatory
state in the brain. Additionally, inhibition of TNFα signaling
by the deletion of TNFRI and II in the 3XTg mice also
showed reduced amyloid load [21]. Since TNFα is another
M1 cytokine, the deletion of its signaling represents an
artificial suppression of the M1 inflammatory state. Finally,
LPS stimulates the secretion of IL-1β, TNFα, and IL-6; all M1
cytokines [6, 33]. LPS has been shown in several studies to
significantly lower amyloid load in APP/PS1 transgenic mice.
The influence of other inflammatory states (M2) on
amyloid load is less established. Few studies have directly
targeted any of the M2 inflammatory pathways to establish
cause-effect relationships between these states and amyloid
deposition. The overexpression of TGFβ may represent a
bias toward the M2c inflammatory state however, in the
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Figure 2: Stimulation of BV2 cultured microglial cells to polarize the response to M1, M2a, M2b, or M2c. BV2 microglial cells were cultured
in normal DMEM media. When confluent, cell media was changed to serum-free DMEM media for 24 hours. Then media was changed
to either DMEM plus IFNγ (2.5 ng/mL) to stimulate an M1 response (a), DMEM plus IL-4 (20 ng/mL) and IL-13 (20 ng/mL) to stimulate
an M2a response (b), DMEM plus immune complexes prepared as described in [32] (5 μg/mL Aβ coated with IgG) to stimulate an M2b
response (c), DMEM plus IL-10 (10 ng/mL) to stimulate an M2c response (d), or DMEM alone to act as an untreated control. Cells were
then harvested 12 hours after the start of treatment. We repeated the experiments 3 times, each on separate cultures of different passage
numbers. Data are shown as fold change compared to untreated control BV2 cells. ∗P < 0.05 and ∗∗P < 0.01.
absence of a characterization of the inflammatory milieu in
these mice it is impossible to draw conclusions. It is appar-
ent, however, from studies performed in aged transgenic
mice that as amyloid accumulates in the brains of mice,
the inflammatory state becomes increasingly polarized to
the M2a inflammatory state. Also, my laboratory recently
showed that lithium treatment enhances the M2a and M2c
inflammatory phenotypes in APPSwDI/NOS2−/− transgenic
mice and increases amyloid deposition in the absence of
changes in total Aβ measured biochemically. Until further
studies are performed that directly enhance the M2a state
using agents identified in the macrophage literature the exact
relationship between the M2a state and amyloid deposition
will remain unknown.
The relationship between neurofibrillary tangle pathol-
ogy and the inflammatory state of the brain is relatively
understudied in comparison to amyloid pathology. The
few studies that have been done to establish relationships
of hyperphosphorylated tau and neuroinflammation would
suggest an opposite relationship to that of amyloid and
neuroinflammation. Where M1 inflammatory phenotypes
appear to ameliorate the amyloid pathology in numerous
studies, induction of M1 phenotypes in tau transgenic mice
or cell culture results in the exacerbation of tau pathology.
LPS injection into the brains of rTg4510 tau transgenic
mice has shown that the tau hyperphosphorylation and
neurofibrillary tangle pathology are increased due to the
LPS. Importantly, this study used an identical protocol to
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that used in APP/PS1 mice to show amyloid reductions
due to LPS. Also, LPS injection in the 3XTg model of
amyloid and tau pathology showed exacerbation of tau
hyperphosphorylation after LPS injection [9]. Additionally,
IL-1β treatment of microglia/neuron cocultures results in
significant hyperphosphorylation of tau protein in the
neuron [23]. Since IL-1β is an M1 cytokine, this again
suggests that the M1 inflammatory state worsens the tau
pathology associated with AD. Finally, my laboratory showed
that biasing APPSwDI/NOS2−/− mice to the M2a state
ameliorates tau hyperphosphorylation normally present in
these mice.
Little has been studied in the human AD brain with
respect to neuroinflammatory profiles, where a complete
spectrum of M1 and M2 inflammatory markers has been
examined. It has been shown that human AD brain is capable
of expressing an array of inflammatory markers spanning the
M1, M2a, M2b, and M2c inflammatory states [34]. Addi-
tionally, data from the ADAPT clinical trial that studied the
preventative properties of nonsteroidal anti-inflammatory
drugs (NSAIDs) in AD suggest that neuroinflammation may
be complex and variable in the human population, since a
subset of patients responded well to NSAIDs, while others
declined more rapidly in response to the same NSAID
[35]. Also, immunotherapy trials continue to show amyloid
reductions in humans, while tau pathology remains relatively
unchanged [36]. Future studies in humans should be focused
on identifying the relationship between the pathologies of
AD and the neuroinflammatory states.
5. Summary and Conclusions
In summary, this paper has described that the macrophage
inflammatory states of M1, M2a, M2b, and M2c, that are
extremely well characterized in the immunology field, can be
applied when examining the inflammatory state of the brain.
By applying these states to the body of literature on the role
of neuroinflammation in AD, the field can begin to establish
cause-effect relationships for each neuroinflammatory state.
It can be concluded that neuroinflammation is a complex,
diverse process that can be characterized by examining a
profile of markers associated with distinct inflammatory
states. Finally, it is essential that more attention be focused
on identifying relationships between each inflammatory state
and each AD pathology so that the AD field can better target
in a more directed, personalized manner to therapeutically
treat AD.
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